5.20
Cholinerge Antagonisten: Pharmakokinetik
Cholinerge Antagonisten— wie Antimuskarinika— sind als orale, topische, okulare, parenterale und inhalative Formulierungen erhältlich. Die meisten Ant…
Cholinerge Antagonisten – wie z. B. Antimuskarinika – werden entweder oral, als Augentropfen, als transdermale Pflaster, als Aerosole oder als Injektionen verabreicht.
Es sei daran erinnert, dass die quartären Antimuskarinika ionisch sind, was zu ihrer geringen Lipidlöslichkeit und einer eingeschränkten Durchdringung der BHS führt. Darüber hinaus werden sie schlecht aus dem Darm, der Haut oder dem Auge aufgenommen.
Im Gegensatz dazu haben tertiäre Derivate eine höhere Lipidlöslichkeit und werden sowohl zentral als auch peripher gut resorbiert.
Da diese Wirkstoffe eine unterschiedliche Wirkungsdauer haben, werden sie als SAMA und LAMA klassifiziert.
Sie werden in der Leber durch Hydrolyse oder Konjugation verstoffwechselt und über den Urin ausgeschieden.
Die Wirkung von Antimuskarinika ist ausgeprägt, wenn sie aufgrund ihrer additiven Nebenwirkungen zusammen mit Arzneimitteln mit anticholinergen Eigenschaften wie Antihistaminika, Antipsychotika oder Antidepressiva verabreicht werden.
Schließlich ist bekannt, dass Antimuskarinika die peristaltische Bewegung des Magens teilweise unterdrücken, die Magenentleerung verzögern und zu einer langsamen Resorption von gleichzeitig verabreichten Arzneimitteln führen.
View the full transcript and gain access to JoVE Core videos
Q1: What are the different routes of administration for cholinergic antagonists?
Cholinergic antagonists are administered through multiple routes including oral formulations, topical eye drops, transdermal patches, inhalational aerosols or powders, and injections. Most antimuscarinics are available as oral formulations, while scopolamine is delivered as a topical patch. Ipratropium and tiotropium are available as inhalation aerosols or powders, and atropine, tropicamide, and cyclopentolate are topically instilled in the eye.
Q2: How does the chemical structure of antimuscarinics affect their absorption and distribution?
Quaternary antimuscarinics are ionic with low lipid solubility, resulting in poor absorption from the gut, skin, or eye and restricted penetration to the blood-brain barrier. Tertiary derivatives have higher lipid solubility and are well-absorbed both centrally and peripherally. When inhaled, quaternary antimuscarinics have limited systemic absorption due to their reduced lipid solubility.
Q3: How are antimuscarinics metabolized and eliminated from the body?
Antimuscarinics undergo hepatic metabolism through hydrolysis or conjugation and are primarily excreted via urine. Atropine rapidly metabolizes in the liver and is excreted unchanged in the urine. Most swallowed ipratropium and tiotropium are excreted through feces, while elimination of quaternary compounds is generally slower than tertiary agents.
Q4: What is the difference between short-acting and long-acting antimuscarinics?
Antimuscarinics are classified based on their duration of action as short-acting or long-acting agents. Short-acting antimuscarinics include ipratropium, while long-acting agents include glycopyrrolate, tiotropium, and aclidinium. This classification helps determine dosing frequency and clinical application for different therapeutic conditions and patient needs.
Q5: Which drugs interact with antimuscarinics and why is this clinically significant?
Antimuscarinics interact with tricyclic antidepressants, antihistamines, antianxiety agents, and antipsychotics, exacerbating antimuscarinic side effects due to additive anticholinergic properties. Additionally, antacids can increase stomach pH and form complexes with antimuscarinics, reducing their absorption. These interactions require careful monitoring during co-administration.
Q6: How do antimuscarinics affect gastric motility and drug absorption?
Antimuscarinics partially suppress peristaltic movement of the stomach, delaying gastric emptying and slowing the absorption of co-administered drugs. This effect can significantly impact the bioavailability and onset of action of other medications taken concurrently with antimuscarinics, requiring dose timing adjustments.
Q7: Why do quaternary antimuscarinics have limited systemic absorption when inhaled?
Quaternary antimuscarinics are ionic compounds with low lipid solubility, which restricts their ability to cross biological membranes. When inhaled, this reduced lipid solubility results in limited systemic absorption, allowing these agents to act primarily at local respiratory sites with minimal systemic effects and reduced side effects.